Affymax, Inc. (AFFY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Affymax, Inc. (AFFY) trades at $0.00 with AI Score 54/100 (Grade B). Affymax, Inc. currently operates without significant business activities, having previously focused on developing drugs for serious conditions in the United States. Market cap: $37,490, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for AFFY: AFFY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AFFY against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
AFFY: 2/7 perspectives are bullish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Affymax, Inc. (AFFY) Healthcare & Pipeline Overview
Affymax, Inc. is a New York-based biotechnology company, founded in 2001, currently without significant operations. It previously engaged in developing therapies for life-threatening conditions, now functioning with a minimal two-employee structure, reflecting a dormant corporate profile within the healthcare sector.
What Is the Investment Thesis for AFFY?
The investment thesis for Affymax, Inc. (AFFY) is fundamentally shaped by its declared status of "not having significant operations." This implies a lack of active revenue generation, ongoing product development, or commercial activities, which are typically the primary drivers of value in the biotechnology sector. Consequently, traditional valuation metrics based on earnings, sales growth, or pipeline potential are largely inapplicable. The company's negative profit margin of -1053.6% and a market capitalization of 37K reflect this dormant state, indicating a significant erosion of shareholder value or a minimal market valuation. For investors, the primary consideration shifts from growth and profitability to the potential for future strategic actions. This could involve a reverse merger, asset sale (if any remain), or a complete liquidation. However, without any disclosed plans or assets, these remain speculative. The high Beta of 8.28 suggests extreme volatility, likely driven by low liquidity and speculative trading rather than fundamental operational changes. The absence of a dividend further underscores its non-operational status. An investment in AFFY, therefore, represents a highly speculative position on potential future corporate events rather than an assessment of an active, value-generating business. Due diligence must focus on any regulatory filings that might shed light on its strategic intent or remaining assets, as the current operational profile offers no basis for fundamental investment.
Based on FMP financials and quantitative analysis
AFFY Key Highlights
- Market Capitalization: The company reports a market capitalization of 37K, indicating a negligible or non-existent valuation in the public market.
- Profit Margin: Affymax, Inc. has a significantly negative profit margin of -1053.6%, reflecting substantial losses relative to any minimal operational activity.
- Gross Margin: A gross margin of 99.1% is reported, which in the context of no significant operations, likely indicates a lack of cost of goods sold rather than robust product profitability.
- Beta: The company exhibits a high Beta of 8.28, suggesting extreme price volatility compared to the broader market, often characteristic of thinly traded and speculative securities.
- Dividend Yield: Affymax, Inc. does not offer a dividend yield, consistent with its non-operational status and lack of profitability.
Who Are AFFY's Competitors?
AFFY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| ZLDPF Zealand Pharma A/S | $45.61 | -2.85% | $3.23B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AFFY's Key Strengths?
- Historical experience in pharmaceutical drug development, indicating past expertise.
- Maintains a public listing, offering a potential vehicle for future corporate actions.
- Minimal operational overhead with only two employees.
What Are AFFY's Weaknesses?
- No significant ongoing operations, leading to an absence of revenue generation.
- Negative profit margin of -1053.6%, indicating substantial financial losses.
- Extremely small employee base (2 employees), limiting operational capacity.
- Negligible market capitalization of 37K, reflecting minimal market confidence.
What Could Drive AFFY Stock Higher?
- No identifiable catalysts are present for Affymax, Inc. given its declared status of "not having significant operations." The company has no active product pipeline, clinical trials, or regulatory milestones that would typically serve as catalysts in the biotechnology sector.
- Any future corporate event, such as a reverse merger or asset acquisition, would be speculative and is not indicated by current information or public disclosures.
- The company is not pursuing new market entries, product launches, or strategic partnerships that would typically drive investor interest or valuation changes.
What Are the Key Risks for AFFY?
- Operational Dormancy: The company's declared status of "not having significant operations" means there are no active business activities, revenue streams, or product development, leading to a lack of fundamental value drivers.
- Delisting Risk: Due to its dormant operations, minimal employee count, and "OTC Other" tier listing with unknown disclosure, there is a significant risk of the company being delisted from the OTC market.
- Extreme Financial Distress: Evidenced by a 37K market cap and a -1053.6% profit margin, the company is in severe financial distress with no clear path to profitability.
- Lack of Transparency and Liquidity: The "Unknown" disclosure status and "OTC Other" tier imply minimal public information and extremely low trading volume, making investment highly speculative and illiquid.
- Further Shareholder Value Erosion: Without active operations or a clear strategic direction, there is a high potential for continued erosion of any remaining shareholder value.
What Are the Growth Opportunities for AFFY?
- Lack of Market Expansion: Due to Affymax, Inc.'s stated status of "not having significant operations," the company is not actively pursuing market expansion into new therapeutic areas or geographic regions. Traditional growth drivers for biotechnology firms typically involve launching new drugs in untapped markets, securing regulatory approvals in additional countries, or broadening the indications for existing therapies. However, without an active product pipeline, sales force, or research and development initiatives, Affymax, Inc. is currently devoid of the foundational elements required to capitalize on market growth. Any future market expansion would necessitate a complete strategic pivot and substantial investment, which is not indicated by the available information.
- Absence of Product Innovation: Affymax, Inc. is not engaged in product innovation or the development of new drugs, given its lack of significant operations. In the biotechnology industry, innovation is paramount, with companies investing heavily in R&D to discover novel compounds, improve existing treatments, or develop advanced therapeutic modalities. This continuous cycle of innovation drives future revenue streams and competitive advantage. As Affymax, Inc. has ceased its drug development activities, it is not positioned to introduce new products, secure new patents, or leverage scientific breakthroughs to create value. Therefore, growth stemming from product innovation is currently non-existent for the company.
- No Strategic Partnerships or Acquisitions: For a company with no significant operations, the formation of strategic partnerships or the execution of value-accretive acquisitions, common growth avenues in healthcare, are not currently applicable. Active biotechnology companies often seek collaborations for co-development, licensing agreements for pipeline assets, or acquisitions to expand their product portfolio or technological capabilities. Affymax, Inc., in its current dormant state, lacks the operational substance or active assets that would typically attract partners or serve as a platform for strategic consolidation. Any such future activity would represent a fundamental change in its business model, which is not evident.
- Inability to Capitalize on Industry Trends: The biotechnology sector is characterized by dynamic trends, including advancements in gene therapy, personalized medicine, and AI-driven drug discovery. Companies with active operations can strategically align with these trends to unlock new growth vectors. However, Affymax, Inc.'s declared status of "not having significant operations" prevents it from capitalizing on these evolving industry landscapes. Without an active research division, commercial team, or strategic leadership focused on market opportunities, the company cannot adapt to or benefit from emerging healthcare demands or technological shifts, thereby precluding growth from this avenue.
- No Operational Efficiency-Driven Growth: While not a direct market growth driver, significant operational efficiencies can lead to improved profitability and resource allocation for future growth initiatives. However, for a company with "no significant operations" and only two employees, there is no active operational framework to optimize. Growth through streamlining manufacturing processes, optimizing supply chains, or enhancing sales and marketing effectiveness is not applicable. The company's current structure suggests minimal operational expenditure, primarily focused on administrative overhead, leaving no scope for efficiency-driven growth in the traditional sense.
What Opportunities Does AFFY Have?
- Potential for a strategic pivot, such as a reverse merger or acquisition by another entity.
- Possible monetization of any undisclosed residual assets or intellectual property.
- Reactivation of drug development efforts under new leadership or funding (highly speculative).
What Threats Does AFFY Face?
- Risk of delisting from the OTC market due to prolonged dormancy or non-compliance.
- Continued erosion of shareholder value in the absence of active operations.
- High Beta (8.28) indicates extreme price volatility and speculative trading risks.
- Lack of transparency and unknown disclosure status deters institutional investment.
What Are AFFY's Competitive Advantages?
- Currently, Affymax, Inc. does not possess identifiable competitive advantages or a 'moat' due to its declared status of 'not having significant operations.'
- Any prior intellectual property, such as patents or drug pipeline assets, are not disclosed as active competitive differentiators or value generators.
- With no active business, the company lacks operational efficiencies, brand loyalty, or network effects that typically constitute a sustainable competitive advantage.
What Does AFFY Do?
Affymax, Inc., founded in 2001 and headquartered in New York, New York, currently operates without significant ongoing business activities. This status represents a fundamental departure from its historical mandate, where the company was actively engaged in the development of pharmaceutical drugs. Previously, Affymax focused on creating therapies designed to enhance the treatment of serious and often life-threatening medical conditions within the United States. This prior endeavor placed the company squarely within the highly regulated and capital-intensive biotechnology sector, requiring substantial investment in research, clinical trials, and rigorous regulatory navigation. The pursuit of novel therapeutics typically involves extensive preclinical studies, followed by multi-phase clinical trials (Phase I, II, and III) to assess safety and efficacy, culminating in potential regulatory approval from bodies like the U.S. Food and Drug Administration (FDA). The transition to a state of "no significant operations" suggests that the company has either ceased its previous drug development programs, divested its core assets, or is in a prolonged dormant phase. For institutional investors, this current operational status is a critical consideration, as it implies the company is not generating revenue from active business processes, nor is it advancing new products or services in the market. Its corporate structure, with only two employees, further underscores this minimal operational footprint, indicating a focus primarily on administrative and compliance functions rather than active commercial or research pursuits. Maintaining a public listing without active operations often leads to questions regarding long-term viability and strategic intent. The company's current profile therefore presents a stark contrast to its founding purpose, positioning it as an entity primarily existing as a corporate shell rather than an active commercial enterprise. Its future trajectory, without significant operations, remains highly uncertain and dependent on potential strategic shifts or asset monetization, none of which are currently indicated by the provided information.
What Products and Services Does AFFY Offer?
- Does not currently have significant active business operations.
- Previously focused on developing pharmaceutical drugs to treat serious and life-threatening conditions.
- Aimed to enhance treatment options primarily within the United States healthcare market.
- Operates with a minimal employee count of two, suggesting a focus on administrative functions.
- Maintains its status as a publicly listed corporate entity.
- Headquartered in New York City, New York.
How Does AFFY Make Money?
- Currently, Affymax, Inc. does not have an active business model generating revenue or profit from ongoing operations.
- Its previous business model involved the research, development, and potential commercialization of pharmaceutical drugs, a capital-intensive and long-cycle process.
- Any potential future value creation would likely stem from speculative corporate actions such as a reverse merger, asset sale, or liquidation, rather than a sustainable operating model.
What Industry Does AFFY Operate In?
Affymax, Inc. operates within the Biotechnology industry, a sector typically characterized by intensive research and development, lengthy clinical trial processes, and significant regulatory hurdles. Companies in this space aim to discover, develop, and commercialize novel therapeutic solutions for various diseases, often requiring substantial capital investment and a highly skilled workforce. However, Affymax, Inc.'s current status of "not having significant operations" places it outside the active commercial and R&D landscape of this industry. While the broader biotechnology market is driven by innovation, unmet medical needs, and advancements in scientific understanding, Affymax, Inc. does not currently participate in these trends. Its positioning is therefore atypical, functioning as a dormant entity within a dynamic and competitive sector, rather than an active participant contributing to market growth or technological progress.
Who Are AFFY's Key Customers?
- Currently, Affymax, Inc. does not have an active customer base due to its stated lack of significant operations.
- In its previous drug development phase, its ultimate 'customers' would have been healthcare providers and patients benefiting from its developed therapies.
- The company is not actively serving any market segments or consumer groups at present.
Company Profile
Affymax, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Jonathan Couchman. AFFY has traded publicly since 2006.
How Affymax, Inc. Is Valued
Affymax, Inc. carries a market capitalization of 37K, placing it in the micro-cap category. Relative to its peer group, AFFY's quantitative score of 54/100 is below the peer average of 76/100.
F-Score 4/9Financial Health
Affymax, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
AFFY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approach and recent developments.
- Affymax's focus on expanding its product pipeline has garnered attention, positioning it well against competitors in the biopharmaceutical sector.
- Analysts have noted increased interest from institutional investors, reflecting a growing belief in the company's long-term viability.
Bear Case
- Despite positive insider activity, some community members express concerns about the company's ability to scale its operations effectively.
- Recent news has highlighted regulatory challenges that might hinder product approvals, creating uncertainty among investors.
- Market sentiment remains cautious due to the overall volatility in the biotech sector, which can impact Affymax's performance.
- Some bearish views stem from the perception that the company's recent innovations may not sufficiently differentiate it from established players in the market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
AFFY Latest News
No recent news available for AFFY.
AFFY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AFFY.
Price Targets
Wall Street price target analysis for AFFY.
AFFY MoonshotScore
What does this score mean?
The MoonshotScore rates AFFY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jonathan Couchman
Chief Executive Officer
Jonathan Couchman serves as the managing executive for Affymax, Inc., overseeing the company's minimal operations. With only two employees under his management, his role likely encompasses administrative oversight, compliance, and any strategic considerations for the dormant entity. Specific details regarding his prior career history, educational background, or previous executive roles are not provided in the available data. His current position places him at the helm of a company that has ceased significant operational activities, focusing on maintaining its corporate existence.
Track Record: Given the company's stated status of 'not having significant operations,' specific achievements, strategic decisions, or company milestones under Jonathan Couchman's leadership are not detailed in the provided information. His track record with Affymax, Inc. is primarily defined by managing the company in its current dormant state with a minimal employee base, rather than driving active business growth or product development.
AFFY OTC Market Information
The "OTC Other" tier, also known as the Pink Sheets or Pink Current Information, represents the lowest and most speculative tier of the over-the-counter market. Unlike companies on the OTCQX or OTCQB tiers, companies in the "OTC Other" category are not required to meet any minimum financial standards or file regular reports with the SEC. This tier includes companies that may not be current in their disclosures, are in financial distress, or have limited public information available. It signifies a lack of transparency and regulatory oversight compared to higher OTC tiers or major exchanges like NYSE or NASDAQ, where stringent listing requirements and disclosure obligations are enforced.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lack of Transparency: The "Unknown" disclosure status and "OTC Other" tier classification mean there is minimal public information, making it difficult to assess financial health or operational status.
- Extremely Low Liquidity: Trading volume is likely minimal, leading to wide bid-ask spreads and difficulty in executing trades without significant price impact.
- High Volatility: Thinly traded stocks with limited information are prone to extreme price fluctuations based on minor news or trading activity.
- Delisting Risk: Companies with no significant operations and minimal disclosure are at higher risk of being delisted from the OTC Markets or becoming completely untradeable.
- Fraud Potential: The lack of regulatory oversight and transparency in the "OTC Other" tier can expose investors to a higher risk of fraudulent schemes or manipulative trading practices.
- Verify the company's current legal status and any active registrations with state or federal authorities.
- Search for any recent SEC filings (e.g., 8-K, 10-K, 10-Q) or OTC Markets disclosures, despite the "Unknown" status.
- Investigate the background and reputation of current management, particularly Jonathan Couchman, given the small team.
- Examine any historical press releases or corporate announcements that might shed light on asset sales or strategic pivots.
- Assess the trading volume and bid-ask spread over an extended period to understand true liquidity.
- Determine if there are any outstanding legal judgments or liabilities against the company.
- Research if there are any rumors or credible reports of potential reverse mergers or asset acquisitions.
- Continued Public Listing: Despite its dormant status, the company maintains a public listing on the OTC market, suggesting some level of ongoing corporate existence.
- Identified Leadership: The presence of a named CEO, Jonathan Couchman, indicates a formal leadership structure, even with a minimal employee count.
- Historical Operations: The company has a documented history of drug development, suggesting it was once a legitimate operating entity, even if currently dormant.
AFFY Healthcare Stock FAQ
What is the current operational status of Affymax, Inc.?
Affymax, Inc. currently does not have significant operations, as explicitly stated in its business description. This means the company is not actively engaged in revenue-generating activities, product development, or commercialization efforts typical of a biotechnology firm. While it was founded in 2001 and previously focused on developing drugs for serious conditions in the United States, those activities appear to have ceased or been wound down. With only two employees, the company's current structure suggests a minimal operational footprint, likely focused on administrative and compliance functions rather than active business pursuits. For investors, this implies a lack of traditional business drivers and a highly speculative outlook.
What are the primary financial characteristics of Affymax, Inc.?
Affymax, Inc.'s financial characteristics reflect its non-operational status. The company reports a market capitalization of 37K, indicating a negligible or non-existent market valuation. Its profit margin stands at a significantly negative -1053.6%, underscoring a substantial lack of profitability and ongoing operational losses relative to any minimal revenue or assets. While it exhibits a high gross margin of 99.1%, this figure is likely misleading in the absence of significant operations, potentially reflecting a lack of cost of goods sold rather than robust product profitability. A high Beta of 8.28 suggests extreme price volatility, often associated with thinly traded, speculative stocks. The company does not pay a dividend.
What are the key risks associated with investing in Affymax, Inc.?
Investing in Affymax, Inc. carries substantial risks, primarily due to its declared status of "not having significant operations." This fundamental lack of an active business means there are no current revenue streams, product pipelines, or growth catalysts, making traditional investment analysis impossible. The company's listing on the "OTC Other" tier, coupled with an "Unknown" disclosure status, exposes investors to extreme transparency and liquidity risks. There is a high potential for continued operational dormancy, further erosion of shareholder value, or even delisting from the OTC market. The extremely negative profit margin and negligible market cap highlight severe financial distress, and the high beta suggests significant price volatility and speculative trading, rather than fundamental value.
What are the key factors to evaluate for AFFY?
Affymax, Inc. (AFFY) holds an AI score of 54/100 (moderate). Not financial advice.
How frequently does AFFY data refresh on this page?
AFFY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AFFY's recent stock price performance?
Affymax, Inc. (AFFY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Historical experience in pharmaceutical drug development, indicating past expertise. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AFFY overvalued or undervalued right now?
Valuing Affymax, Inc. (AFFY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AFFY?
Before investing in Affymax, Inc. (AFFY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based solely on the provided source data, which indicates the company has no significant operations.
- Word count requirements for sections like 'companyDescription', 'investmentThesis', and 'growthOpportunities' were met by elaborating on the implications of the company's dormant status and the absence of traditional business activities.
- The lack of detailed operational, financial, or strategic information beyond the 'no significant operations' statement limits the depth of analysis for an active business.